Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Deferred Tax Liability for 6 consecutive years, with $548000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 1.62% to $548000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $548000.0, a 1.62% decrease, with the full-year FY2024 number at $548000.0, down 94.12% from a year prior.
  • Non-Current Deferred Tax Liability was $548000.0 for Q3 2025 at Caribou Biosciences, roughly flat from $548000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $9.3 million in Q4 2023 to a low of $155000.0 in Q2 2021.
  • A 5-year average of $1.1 million and a median of $512000.0 in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: surged 2345.14% in 2023, then tumbled 94.12% in 2024.
  • Caribou Biosciences' Non-Current Deferred Tax Liability stood at $3.3 million in 2021, then plummeted by 88.53% to $381000.0 in 2022, then soared by 2345.14% to $9.3 million in 2023, then crashed by 94.12% to $548000.0 in 2024, then changed by 0.0% to $548000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non-Current Deferred Tax Liability are $548000.0 (Q3 2025), $548000.0 (Q2 2025), and $548000.0 (Q1 2025).